1 Min Read
Oct 4 (Reuters) - Motif Bio Plc
* ANNOUNCES POSITIVE TOPLINE RESULTS FOR ICLAPRIM IN REVIVE-2 PHASE 3 STUDY
* NDA SUBMISSION EXPECTED IN Q1 OF 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.